Vancomycin-Resistant Enterococcus faecium Infections Pipeline Review, H2 2016, latest research study provides in depth analysis on Cellular Tumor Antigen P53 (Tumor Suppressor P53 or Antigen NY-CO-13) targeted pipeline therapeutics.
Vancomycin-Resistant Enterococcus faecium Infections therapeutics industry report provides comprehensive information on the therapeutics under development for Vancomycin-Resistant Enterococcus faecium Infections, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Vancomycin-Resistant Enterococcus faecium Infections and features dormant and discontinued projects.
Pathogenic strains of Enterococcus resistant to vancomycin are termed as Vancomycin-Resistant Enterococcus (VRE). Vancomycin-resistant enterococci have become a source of nosocomial infections. The symptoms of Vancomycin-resistant enterococci infection depend on where the infection lies. The bacteria usually infect the intestines, wounds and urinary tract. In case of wound infection, the area infected will be red and tender as well as swollen. In case of urinary tract infection, back pain and burning could occur when urination takes place. Other symptoms include nausea, fever, chills, severe headaches and diarrhea. Prevention requires effective hygienic practices.
Browse more detail information about Vancomycin-Resistant Enterococcus faecium Infections market report at: http://www.absolutereports.com/vancomycin-resistant-enterococcus-faecium-infections-pipeline-review-h2-2016-10435015
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Key players in Vancomycin-Resistant Enterococcus faecium Infections – Pipeline Review, H2 2016:
Get a PDF Sample of Vancomycin-Resistant Enterococcus faecium Infections Market Research Report at: http://www.absolutereports.com/enquiry/request-sample/10435015
Drug Profiles of Included in Vancomycin-Resistant Enterococcus faecium Infections Therapeutics Development Market Report
And other drug profiles
Have any query? ask our expert @ http://www.absolutereports.com/enquiry/pre-order-enquiry/10435015
Key Topics Covered:
2.Vancomycin-Resistant Enterococcus faecium Infections Overview
3.Vancomycin-Resistant Enterococcus faecium Infections Therapeutics Development
4.Pipeline Products for Vancomycin-Resistant Enterococcus faecium Infections – Overview
5.Pipeline Products for Vancomycin-Resistant Enterococcus faecium Infections – Comparative Analysis
6.Vancomycin-Resistant Enterococcus faecium Infections – Therapeutics under Development by Companies
7.Vancomycin-Resistant Enterococcus faecium Infections – Therapeutics under Investigation by Universities/Institutes
8.Vancomycin-Resistant Enterococcus faecium Infections Products Glance
9.Late Stage Products
10.Clinical Stage Products
11.Early Stage Products
12.Vancomycin-Resistant Enterococcus faecium Infections – Products under Development by Companies
13.Vancomycin-Resistant Enterococcus faecium Infections – Products under Investigation by Universities/Institutes
14.Vancomycin-Resistant Enterococcus faecium Infections – Companies Involved in Therapeutics Development
15.Vancomycin-Resistant Enterococcus faecium Infections Drug Profiles
16.Vancomycin-Resistant Enterococcus faecium Infections Dormant Projects
17.Vancomycin-Resistant Enterococcus faecium Infections Discontinued Products
18.Vancomycin-Resistant Enterococcus faecium Infections Featured News & Press Releases
Get Discount on Vancomycin-Resistant Enterococcus faecium Infections Market Research Report at: http://www.absolutereports.com/enquiry/request-discount/10435015
List of Tables
List of Figures
Number of Products by Stage and Molecule Types, H2 2016 45